Expanding CAR-T cell immunotherapy horizons through microfluidics

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has shown success in treating blood cancers but faces limitations in solid tumor treatment, safety, and manufacturing scalability.
• Current CAR-T cell production methods are complex, costly, and difficult to scale, hindering wider clinical application.
• Microfluidic technologies offer potential solutions to these manufacturing challenges due to their efficiency and automation capabilities.

Purpose of the Study:

• To provide a comprehensive review of CAR-T cell manufacturing processes.
• To identify challenges in current CAR-T cell production.
• To explore the application of microfluidics in overcoming these challenges and advancing cell-based therapies.

Main Methods:

• Review of existing literature on CAR-T cell manufacturing and microfluidic technologies.
• Analysis of the step-by-step CAR-T cell production process.
• Discussion of microfluidics integration and its impact on efficiency, scalability, and cost-effectiveness.

Main Results:

• Microfluidics can streamline CAR-T cell manufacturing, improving efficiency and scalability.
• Integration of microfluidics addresses key challenges in CAR-T cell production, including safety and cost.
• Microfluidics-based approaches show promise for next-generation CAR constructs and allogeneic cell therapies.

Conclusions:

• Microfluidics integration is a promising strategy to enhance CAR-T cell therapy manufacturing.
• This technology can facilitate the development of CAR-T cell therapies for solid tumors and 'off-the-shelf' products.
• Microfluidics holds significant potential for advancing cell-based cancer immunotherapies.